Replies to post #255759 on Biotech Values

[dewophile]

From your link:

Single Phase 3 trial designed to enroll 200U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation

The phase 2b trial had 300 patients enrolled (albeit at 2 dose levels), missed on the primary endpoint with no favorable trend, and was not statistically significant on mortality
best of luck to the purchasing company if indeed they are running a smaller phase 3 and hope to have success (yes the patients enrolled in the US fared better in the 2b but if they are using that efficacy size in powering assumptions then..

anyway this is irrelevant ot me
in 5 min of googling I can see why the company agreed to be bought for a pittance (again not the point of "the exercise" you said so who cares